Day: October 19, 2024

NX-5948 demonstrated robust clinical activity with objective responses observed in 7 of 9 (77.8%) evaluable Waldenstrom’s patients in the ongoing Phase 1a/1b clinical trial Responses are durable and deepen over time with two patients on treatment for greater than one year Data were presented at the 12th International Workshop on Waldenstrom’s Macroglobulinemia (IWWM-12) SAN FRANCISCO, Oct. 19, 2024 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced the presentation of clinical data from its ongoing Phase 1a/1b clinical trial of NX-5948, an orally bioavailable, brain penetrant degrader of Burton’s tyrosine kinase (BTK), in patients with relapsed/refractory...

SAN DIEGO, Oct. 18, 2024 (GLOBE NEWSWIRE) — Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced that the staff of NYSE Regulation has determined to commence proceedings to delist the warrants — ticker symbol CLDI WS — of Calidi Biotherapeutics, Inc. (the “Company”), each whole warrant exercisable for 1/10th of a share of common stock at an exercise price of $115.00 per whole share of common stock, from the NYSE American. Trading in the Company’s warrants will be suspended immediately. Trading in the Company’s common stock — ticker symbol CLDI — will continue on the NYSE American. NYSE Regulation staff has determined that the Company’s warrants are no longer suitable for listing pursuant to Section 1001...

WARREN, N.J., Oct. 18, 2024 (GLOBE NEWSWIRE) — Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN) is a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers. Since being founded in 2020, Tevogen Bio has taken a unique approach to both drug development and managing its business operations. The company launched is proprietary ExacTcell™ technology, designed to create accessible and disease-specific cellular immunotherapies. Tevogen Bio received 3 U.S. patents, with an additional 9 patents pending, including 2 for Artificial Intelligence, and has filed 12 international applications. Additionally, the company reported positive proof-of-concept clinical trial data for the first clinical product of its proprietary...

VANCOUVER, British Columbia, Oct. 18, 2024 (GLOBE NEWSWIRE) — Apollo Silver Corp. (“Apollo Silver” or the “Company”) (TSX.V:APGO, OTCQB:APGOF, Frankfurt:6ZF0) is pleased to announce that due to significant interest, the Company has elected to further increase the size of its non-brokered private placement and will now offer up to 67,500,000 common shares of the Company (the “Shares”) at a price of $0.20 per Share, for aggregate gross proceeds of up to $13,500,000 (the “Offering”). All securities issued in connection with the Offering will be subject to a four-month hold period from the date of closing. Finder’s fees may be payable on a portion of the funds in accordance with the policies of the TSX Venture Exchange (the “TSX-V”). The Company intends on using the net proceeds from the Offering to continue advancing the Calico Silver...